DK175113B1 - Anvendelse af 5- og 6-leddede heterocycliske forbindelser til fremstilling af et præparat til behandling af patienter inficeret med HIV - Google Patents

Anvendelse af 5- og 6-leddede heterocycliske forbindelser til fremstilling af et præparat til behandling af patienter inficeret med HIV Download PDF

Info

Publication number: DK175113B1
Authority: DK; Denmark
Prior art keywords: dideoxy; imino; compound; methyl; hiv
Prior art date: 1987-12-21

Application number

DK198807081A

Other languages

Danish (da)

English (en)

Other versions

DK708188D0 (da

DK708188A (da

Inventor

Raymond Allen Dwek

Thomas William Rademacher

Georg William John Fleet

Original Assignee

Monsanto Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-12-21

Filing date

1988-12-20

Publication date

2004-06-07

1988-12-20 Application filed by Monsanto Co filed Critical Monsanto Co

1988-12-20 Publication of DK708188D0 publication Critical patent/DK708188D0/da

1989-06-22 Publication of DK708188A publication Critical patent/DK708188A/da

2004-06-07 Application granted granted Critical

2004-06-07 Publication of DK175113B1 publication Critical patent/DK175113B1/da

Links

239000000203 mixture Substances 0.000 title claims description 10
150000000565 5-membered heterocyclic compounds Chemical class 0.000 title 1
150000000644 6-membered heterocyclic compounds Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 107
241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 36
LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 claims abstract description 17
230000002401 inhibitory effect Effects 0.000 claims abstract description 10
OQEBIHBLFRADNM-YUPRTTJUSA-N 2-hydroxymethyl-pyrrolidine-3,4-diol Chemical compound OC[C@@H]1NC[C@H](O)[C@H]1O OQEBIHBLFRADNM-YUPRTTJUSA-N 0.000 claims abstract description 6
OQEBIHBLFRADNM-LMVFSUKVSA-N (2s,3s,4r)-2-(hydroxymethyl)pyrrolidine-3,4-diol Chemical compound OC[C@@H]1NC[C@@H](O)[C@H]1O OQEBIHBLFRADNM-LMVFSUKVSA-N 0.000 claims abstract description 5
150000003839 salts Chemical class 0.000 claims abstract description 5
RVNSAAIWCWTCTJ-ARQDHWQXSA-N (2s,3s,4r)-2-[(1s)-1,2-dihydroxyethyl]pyrrolidine-3,4-diol Chemical compound OC[C@@H](O)[C@@H]1NC[C@@H](O)[C@H]1O RVNSAAIWCWTCTJ-ARQDHWQXSA-N 0.000 claims abstract description 4
OQEBIHBLFRADNM-MROZADKFSA-N 1,4-Dideoxy-1,4-imino-D-ribitol Chemical compound OC[C@H]1NC[C@H](O)[C@@H]1O OQEBIHBLFRADNM-MROZADKFSA-N 0.000 claims abstract description 4
OQEBIHBLFRADNM-UHFFFAOYSA-N D-iminoxylitol Natural products OCC1NCC(O)C1O OQEBIHBLFRADNM-UHFFFAOYSA-N 0.000 claims abstract description 4
NEKWBGYGPTVYPY-UHFFFAOYSA-N (1,2-dihydroxypyrrolidin-2-yl)methanediol Chemical compound OC(O)C1(O)CCCN1O NEKWBGYGPTVYPY-UHFFFAOYSA-N 0.000 claims description 7
RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 2
230000001225 therapeutic effect Effects 0.000 claims description 2
NUKZAGXMHTUAFE-UHFFFAOYSA-N methyl hexanoate Chemical compound CCCCCC(=O)OC NUKZAGXMHTUAFE-UHFFFAOYSA-N 0.000 claims 2
150000002391 heterocyclic compounds Chemical class 0.000 abstract description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 78
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 44
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
239000011541 reaction mixture Substances 0.000 description 26
239000007787 solid Substances 0.000 description 24
239000002904 solvent Substances 0.000 description 23
210000004027 cell Anatomy 0.000 description 21
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
230000002829 reductive effect Effects 0.000 description 17
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
239000003921 oil Substances 0.000 description 16
239000000243 solution Substances 0.000 description 16
WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 15
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
239000007858 starting material Substances 0.000 description 14
230000000694 effects Effects 0.000 description 13
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
238000003818 flash chromatography Methods 0.000 description 12
241000700605 Viruses Species 0.000 description 11
150000001412 amines Chemical class 0.000 description 11
230000015572 biosynthetic process Effects 0.000 description 11
208000030507 AIDS Diseases 0.000 description 10
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
230000008018 melting Effects 0.000 description 10
238000002844 melting Methods 0.000 description 10
238000003786 synthesis reaction Methods 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
230000000120 cytopathologic effect Effects 0.000 description 9
229910052757 nitrogen Inorganic materials 0.000 description 9
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
210000001744 T-lymphocyte Anatomy 0.000 description 8
LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 8
239000003112 inhibitor Substances 0.000 description 8
238000012360 testing method Methods 0.000 description 8
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
239000012230 colorless oil Substances 0.000 description 7
VYOCYWDJTQRZLC-KCDKBNATSA-N deoxyfuconojirimycin Chemical class C[C@@H]1NC[C@@H](O)[C@H](O)[C@@H]1O VYOCYWDJTQRZLC-KCDKBNATSA-N 0.000 description 7
239000001257 hydrogen Substances 0.000 description 7
229910052739 hydrogen Inorganic materials 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
150000002009 diols Chemical class 0.000 description 6
239000006188 syrup Substances 0.000 description 6
235000020357 syrup Nutrition 0.000 description 6
LXBIFEVIBLOUGU-KVTDHHQDSA-N (2r,3r,4r,5r)-2-(hydroxymethyl)piperidine-3,4,5-triol Chemical compound OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-KVTDHHQDSA-N 0.000 description 5
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 5
208000031886 HIV Infections Diseases 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000003814 drug Substances 0.000 description 5
238000001704 evaporation Methods 0.000 description 5
230000008020 evaporation Effects 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 5
230000002458 infectious effect Effects 0.000 description 5
238000007069 methylation reaction Methods 0.000 description 5
229920001467 poly(styrenesulfonates) Polymers 0.000 description 5
230000035755 proliferation Effects 0.000 description 5
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
-1 trifluoroacetic acid salt Chemical class 0.000 description 5
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 5
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
239000002259 anti human immunodeficiency virus agent Substances 0.000 description 4
230000036436 anti-hiv Effects 0.000 description 4
NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 4
239000012467 final product Substances 0.000 description 4
150000003840 hydrochlorides Chemical group 0.000 description 4
238000004255 ion exchange chromatography Methods 0.000 description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
239000002245 particle Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 3
JDVVGAQPNNXQDW-WCMLQCRESA-N Castanospermine Natural products O[C@H]1[C@@H](O)[C@H]2[C@@H](O)CCN2C[C@H]1O JDVVGAQPNNXQDW-WCMLQCRESA-N 0.000 description 3
JDVVGAQPNNXQDW-TVNFTVLESA-N Castinospermine Chemical compound C1[C@H](O)[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CCN21 JDVVGAQPNNXQDW-TVNFTVLESA-N 0.000 description 3
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
241000713340 Human immunodeficiency virus 2 Species 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
239000012267 brine Substances 0.000 description 3
230000003197 catalytic effect Effects 0.000 description 3
229940125773 compound 10 Drugs 0.000 description 3
230000003013 cytotoxicity Effects 0.000 description 3
231100000135 cytotoxicity Toxicity 0.000 description 3
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 3
108010050669 glucosidase I Proteins 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
239000012044 organic layer Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000011734 sodium Substances 0.000 description 3
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000000758 substrate Substances 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
229960005486 vaccine Drugs 0.000 description 3
229960002555 zidovudine Drugs 0.000 description 3
PFYHYHZGDNWFIF-UHFFFAOYSA-N (+)-DMDP Natural products OCC1NC(CO)C(O)C1O PFYHYHZGDNWFIF-UHFFFAOYSA-N 0.000 description 2
PFYHYHZGDNWFIF-KVTDHHQDSA-N 2,5-bis(hydroxymethyl)-3,4-dihydroxypyrrolidine Chemical compound OC[C@H]1N[C@H](CO)[C@@H](O)[C@@H]1O PFYHYHZGDNWFIF-KVTDHHQDSA-N 0.000 description 2
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
SXZYCXMUPBBULW-LECHCGJUSA-N D-(-)-Gulono-gamma-lactone Chemical compound OC[C@@H](O)[C@@H]1OC(=O)[C@H](O)[C@@H]1O SXZYCXMUPBBULW-LECHCGJUSA-N 0.000 description 2
102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 2
101710121417 Envelope glycoprotein Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
208000037357 HIV infectious disease Diseases 0.000 description 2
102100025315 Mannosyl-oligosaccharide glucosidase Human genes 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
AYJRCSIUFZENHW-UHFFFAOYSA-L barium carbonate Chemical compound [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 description 2
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
230000027455 binding Effects 0.000 description 2
238000009739 binding Methods 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000030833 cell death Effects 0.000 description 2
229940125904 compound 1 Drugs 0.000 description 2
229940125782 compound 2 Drugs 0.000 description 2
229940126214 compound 3 Drugs 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000000284 extract Substances 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
239000008103 glucose Substances 0.000 description 2
239000003316 glycosidase inhibitor Substances 0.000 description 2
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
150000004678 hydrides Chemical class 0.000 description 2
238000011835 investigation Methods 0.000 description 2
238000005342 ion exchange Methods 0.000 description 2
150000003951 lactams Chemical class 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
238000000034 method Methods 0.000 description 2
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
229910052763 palladium Inorganic materials 0.000 description 2
239000000047 product Substances 0.000 description 2
JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000010998 test method Methods 0.000 description 2
210000002845 virion Anatomy 0.000 description 2
JDVVGAQPNNXQDW-LQOSVEJXSA-N (1r,6s,7s,8s,8as)-1,2,3,5,6,7,8,8a-octahydroindolizine-1,6,7,8-tetrol Chemical compound C1[C@H](O)[C@H](O)[C@@H](O)[C@@H]2[C@H](O)CCN21 JDVVGAQPNNXQDW-LQOSVEJXSA-N 0.000 description 1
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
PZGVJCJRMKIVLJ-YMDUGQBDSA-N (2r,3r,4s)-2-(hydroxymethyl)pyrrolidine-3,4-diol;hydrochloride Chemical compound Cl.OC[C@H]1NC[C@H](O)[C@@H]1O PZGVJCJRMKIVLJ-YMDUGQBDSA-N 0.000 description 1
IFRNNJQXHHLGKS-PVCLPBLSSA-N (2s,3s,4r)-2-[(1s)-1,2-dihydroxyethyl]pyrrolidine-3,4-diol;hydrochloride Chemical compound Cl.OC[C@@H](O)[C@@H]1NC[C@@H](O)[C@H]1O IFRNNJQXHHLGKS-PVCLPBLSSA-N 0.000 description 1
IVWWFWFVSWOTLP-YVZVNANGSA-N (3'as,4r,7'as)-2,2,2',2'-tetramethylspiro[1,3-dioxolane-4,6'-4,7a-dihydro-3ah-[1,3]dioxolo[4,5-c]pyran]-7'-one Chemical compound C([C@@H]1OC(O[C@@H]1C1=O)(C)C)O[C@]21COC(C)(C)O2 IVWWFWFVSWOTLP-YVZVNANGSA-N 0.000 description 1
KEJGAYKWRDILTF-VVULQXIFSA-N (3ar,5s,6r,6ar)-5-[(4r)-2,2-dimethyl-1,3-dioxolan-4-yl]-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-6-ol Chemical compound O1C(C)(C)OC[C@@H]1[C@@H]1[C@@H](O)[C@H]2OC(C)(C)O[C@H]2O1 KEJGAYKWRDILTF-VVULQXIFSA-N 0.000 description 1
VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 1
UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
LXBIFEVIBLOUGU-FSIIMWSLSA-N 1,5-dideoxy-1,5-imino-d-mannitol Chemical compound OC[C@@H]1NC[C@@H](O)[C@H](O)[C@H]1O LXBIFEVIBLOUGU-FSIIMWSLSA-N 0.000 description 1
BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
108010041397 CD4 Antigens Proteins 0.000 description 1
241001107116 Castanospermum australe Species 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
AVVWPBAENSWJCB-CBPJZXOFSA-N D-allofuranose Chemical compound OC[C@@H](O)[C@H]1OC(O)[C@H](O)[C@@H]1O AVVWPBAENSWJCB-CBPJZXOFSA-N 0.000 description 1
WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 description 1
NPOJQCVWMSKXDN-UHFFFAOYSA-N Dacthal Chemical compound COC(=O)C1=C(Cl)C(Cl)=C(C(=O)OC)C(Cl)=C1Cl NPOJQCVWMSKXDN-UHFFFAOYSA-N 0.000 description 1
108010056771 Glucosidases Proteins 0.000 description 1
102000004366 Glucosidases Human genes 0.000 description 1
229940122069 Glycosidase inhibitor Drugs 0.000 description 1
208000008771 Lymphadenopathy Diseases 0.000 description 1
239000012359 Methanesulfonyl chloride Substances 0.000 description 1
YWBPEHFIHKFMMC-UHFFFAOYSA-N N-methyl-DMDP Natural products CN1C(CO)C(O)C(O)C1CO YWBPEHFIHKFMMC-UHFFFAOYSA-N 0.000 description 1
239000007832 Na2SO4 Substances 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
150000003797 alkaloid derivatives Chemical class 0.000 description 1
WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
238000003556 assay Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
238000005574 benzylation reaction Methods 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
244000309464 bull Species 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
229940125797 compound 12 Drugs 0.000 description 1
229940125810 compound 20 Drugs 0.000 description 1
239000012043 crude product Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
150000001923 cyclic compounds Chemical class 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Chemical compound CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000012065 filter cake Substances 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
230000007614 genetic variation Effects 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
239000010410 layer Substances 0.000 description 1
208000018555 lymphatic system disease Diseases 0.000 description 1
238000003760 magnetic stirring Methods 0.000 description 1
108010009689 mannosyl-oligosaccharide 1,2-alpha-mannosidase Proteins 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
FDNFXHCDOASWAY-UHFFFAOYSA-N methyl 6-oxohexanoate Chemical compound COC(=O)CCCCC=O FDNFXHCDOASWAY-UHFFFAOYSA-N 0.000 description 1
HOVAGTYPODGVJG-ZFYZTMLRSA-N methyl alpha-D-glucopyranoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HOVAGTYPODGVJG-ZFYZTMLRSA-N 0.000 description 1
HOVAGTYPODGVJG-UHFFFAOYSA-N methyl beta-galactoside Natural products COC1OC(CO)C(O)C(O)C1O HOVAGTYPODGVJG-UHFFFAOYSA-N 0.000 description 1
229940050176 methyl chloride Drugs 0.000 description 1
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
AXIPBRXJGSXLHF-UHFFFAOYSA-N piperidine;pyrrolidine Chemical compound C1CCNC1.C1CCNCC1 AXIPBRXJGSXLHF-UHFFFAOYSA-N 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000001902 propagating effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
150000003215 pyranoses Chemical class 0.000 description 1
150000003235 pyrrolidines Chemical class 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
235000019345 sodium thiosulphate Nutrition 0.000 description 1
UYCAUPASBSROMS-AWQJXPNKSA-M sodium;2,2,2-trifluoroacetate Chemical compound [Na+].[O-][13C](=O)[13C](F)(F)F UYCAUPASBSROMS-AWQJXPNKSA-M 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000004448 titration Methods 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
- C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Compounds Of Unknown Constitution (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK198807081A 1987-12-21 1988-12-20 Anvendelse af 5- og 6-leddede heterocycliske forbindelser til fremstilling af et præparat til behandling af patienter inficeret med HIV DK175113B1 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US13621987A	1987-12-21	1987-12-21
US13621987		1987-12-21
US24914488		1988-09-26
US07/249,144 US4999360A (en)	1987-12-21	1988-09-26	Method of inhibiting virus

Publications (3)

Publication Number	Publication Date
DK708188D0 DK708188D0 (da)	1988-12-20
DK708188A DK708188A (da)	1989-06-22
DK175113B1 true DK175113B1 (da)	2004-06-07

Family

ID=26834131

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK198807081A DK175113B1 (da)	1987-12-21	1988-12-20	Anvendelse af 5- og 6-leddede heterocycliske forbindelser til fremstilling af et præparat til behandling af patienter inficeret med HIV

Country Status (16)

Country	Link
US (1)	US4999360A (fr)
EP (1)	EP0322395B1 (fr)
JP (1)	JP2538014B2 (fr)
KR (1)	KR910009994B1 (fr)
AT (1)	ATE87206T1 (fr)
AU (1)	AU607834B2 (fr)
CA (1)	CA1316929C (fr)
DE (1)	DE3879653T2 (fr)
DK (1)	DK175113B1 (fr)
FI (1)	FI93210C (fr)
IE (1)	IE63095B1 (fr)
IL (1)	IL88742A (fr)
NO (1)	NO172340C (fr)
NZ (1)	NZ227410A (fr)
OA (1)	OA08937A (fr)
PT (1)	PT89267B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2086323T3 (es) *	1988-11-03	1996-07-01	Searle & Co	Derivados del didesoxi-arabinitol como compuestos antiviricos.
US4894388A (en) *	1988-12-22	1990-01-16	Monsanto Company	Glycosidase inhibitors and use thereof
US5100797A (en) *	1989-06-27	1992-03-31	Monsanto Company	Fucosidase inhibitors
US5043273A (en) *	1989-08-17	1991-08-27	Monsanto Company	Phosphorylated glycosidase inhibitor prodrugs
IT1239950B (it) *	1990-03-28	1993-11-27	Zambon Spa	Processo per la preparazione di composti con attivita' analgesica centrale
US5536732A (en) *	1990-04-27	1996-07-16	Merrell Pharmaceuticals Inc.	N-derivatives of 1-deoxy nojirimycin
US5252587A (en) *	1990-04-27	1993-10-12	Merrell Dow Pharmaceuticals, Inc.	N-derivatives of 1-deoxy nojirimycin
US5290948A (en) *	1990-09-17	1994-03-01	Mcneilab, Inc.	Process for producing polyhydroxylated piperidines and pyrrolidines and compounds thereof
GB9026271D0 (en) *	1990-12-03	1991-01-16	Alphey Thomas J W	Control of parasitic nematodes(a)
US5258518A (en) *	1992-04-01	1993-11-02	G. D. Searle & Co.	2-substituted tertiary carbinol derivatives of deoxynojirimycin
US5451679A (en) *	1994-03-08	1995-09-19	G. D. Searle & Co.	2-chloro and 2-bromo derivatives of 1,5-iminosugars
AU724003B2 (en) *	1995-09-08	2000-09-07	Novo Nordisk A/S	2-alkylpyrrolidines
CN102399228B (zh) *	2010-09-08	2013-10-16	中国科学院成都生物研究所	N-烷基多羟基哌啶衍生物的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1555654A (en) *	1977-06-25	1979-11-14	Exxon Research Engineering Co	Agricultural burner apparatus
US4065562A (en) *	1975-12-29	1977-12-27	Nippon Shinyaku Co., Ltd.	Method and composition for reducing blood glucose levels
DE3038901A1 (de) *	1980-10-15	1982-05-06	Bayer Ag, 5090 Leverkusen	Verfahren zur herstellung von n-substituierten derivaten des 1-desoxynojirimycins
DE3507019A1 (de) *	1985-02-28	1986-08-28	Bayer Ag, 5090 Leverkusen	Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung
EP0252962B1 (fr) *	1985-12-23	1995-08-23	Fred Hutchinson Cancer Research Center	Regulation de la replication, de l'infection et de la pathogenese retrovirales

1988
- 1988-09-26 US US07/249,144 patent/US4999360A/en not_active Expired - Lifetime
- 1988-12-20 PT PT89267A patent/PT89267B/pt active IP Right Revival
- 1988-12-20 EP EP88870192A patent/EP0322395B1/fr not_active Expired - Lifetime
- 1988-12-20 OA OA59494A patent/OA08937A/fr unknown
- 1988-12-20 DE DE88870192T patent/DE3879653T2/de not_active Expired - Fee Related
- 1988-12-20 FI FI885880A patent/FI93210C/fi not_active IP Right Cessation
- 1988-12-20 CA CA000586466A patent/CA1316929C/fr not_active Expired - Fee Related
- 1988-12-20 KR KR1019880017028A patent/KR910009994B1/ko not_active Expired
- 1988-12-20 NZ NZ227410A patent/NZ227410A/en unknown
- 1988-12-20 IL IL88742A patent/IL88742A/xx not_active IP Right Cessation
- 1988-12-20 JP JP63321868A patent/JP2538014B2/ja not_active Expired - Fee Related
- 1988-12-20 AU AU27068/88A patent/AU607834B2/en not_active Ceased
- 1988-12-20 NO NO885655A patent/NO172340C/no not_active IP Right Cessation
- 1988-12-20 IE IE379488A patent/IE63095B1/en not_active IP Right Cessation
- 1988-12-20 AT AT88870192T patent/ATE87206T1/de not_active IP Right Cessation
- 1988-12-20 DK DK198807081A patent/DK175113B1/da not_active IP Right Cessation

Also Published As

Publication number	Publication date
JP2538014B2 (ja)	1996-09-25
NO172340C (no)	1993-07-07
FI93210B (fi)	1994-11-30
FI93210C (fi)	1995-03-10
IE883794L (en)	1989-06-21
DK708188D0 (da)	1988-12-20
JPH01230517A (ja)	1989-09-14
PT89267B (pt)	1993-12-31
EP0322395A1 (fr)	1989-06-28
US4999360A (en)	1991-03-12
FI885880L (fi)	1989-06-22
NZ227410A (en)	1991-06-25
CA1316929C (fr)	1993-04-27
FI885880A0 (fi)	1988-12-20
NO172340B (no)	1993-03-29
KR910009994B1 (ko)	1991-12-10
AU607834B2 (en)	1991-03-14
IE63095B1 (en)	1995-03-22
IL88742A (en)	1993-08-18
DE3879653D1 (de)	1993-04-29
DE3879653T2 (de)	1993-10-14
PT89267A (pt)	1989-12-29
NO885655D0 (no)	1988-12-20
ATE87206T1 (de)	1993-04-15
AU2706888A (en)	1989-06-22
NO885655L (no)	1989-06-22
DK708188A (da)	1989-06-22
IL88742A0 (en)	1989-07-31
OA08937A (fr)	1989-10-31
EP0322395B1 (fr)	1993-03-24
KR890009389A (ko)	1989-08-01

Legal Events

Date	Code	Title	Description
2005-08-22	PBP	Patent lapsed	Country of ref document: DK

Publication	Publication Date	Title
DK175113B1 (da)	2004-06-07	Anvendelse af 5- og 6-leddede heterocycliske forbindelser til fremstilling af et præparat til behandling af patienter inficeret med HIV
KR102771082B1 (ko)	2025-02-21	케토아미드계 화합물 및 이의 제조 방법, 약학 조성물과 용도
US5030638A (en)	1991-07-09	Method of antiviral enhancement
DK174627B1 (da)	2003-07-28	Forbindelse, farmaceutisk præparat, lægemiddel og anvendelse af 3'-deoxythymidin-2'-en til fremstilling af et farmaceutisk præparat til behandling af retrovirusinfektioner
FR2614533A1 (fr)	1988-11-04	Nouveaux derives peptidiques, leur preparation et leur utilisation comme medicaments
AU596864B2 (en)	1990-05-17	The use of 2',3'-dideoxycytidin-2'-ene(2',3'-dideoxy-2',3'- didehydrocytidine) in treating patients infected with retroviruses
KR20000065885A (ko)	2000-11-15	항바이러스성 피리미딘다이온 유도체 및 그 제조방법
US5089520A (en)	1992-02-18	Method of inhibiting virus
CN109503548B (zh)	2020-08-04	一种丁苯酞衍生物及其制备方法和应用
US5043416A (en)	1991-08-27	Method of inhibiting virus
CN104876950A (zh)	2015-09-02	一种含硫稠杂四环氮杂糖衍生物及其制备方法和应用
Sochacka et al.	1990	Nucleosides. 153. Synthesis of 1-methyl-5-(3-azido-2, 3-dideoxy-. beta.-D-erythro-pentofuranosyl) uracil and 1-methyl-5-(3-azido-2, 3-dideoxy-2-fluoro-. beta.-D-arabinofuranosyl) uracil. The C-nucleoside isostere of 3'-azido-3'-deoxythymidine and its 2'-" up"-fluoro analog
WO1996007409A1 (fr)	1996-03-14	Alcaloides et leurs agents antiviraux
KR950013764B1 (ko)	1995-11-15	피로글루타미드 유도체, 그 제조방법, 및 그것을 함유하는 치매증 치료제
JPH07504405A (ja)	1995-05-18	置換アザスピラン化合物の投与によるｈｉｖ個体ａｉｄｓの遅延方法
KR810000892B1 (ko)	1981-08-17	1,3-디하이드로스피로 [이소벤조푸란-1,4'-피페리딘]류의 제조방법
US6001818A (en)	1999-12-14	Use of 2',3'-dideoxycytidin-2'-ene (2'- ,3'-dideoxy-2'3'-didehydrocytidine) in treating patients infected with retroviruses
EP0260605A2 (fr)	1988-03-23	Ester cyclique d'acide dihydropyridinephosphonique-5
KR810000335B1 (ko)	1981-04-20	1,3-디하이드로 스피로 〔이소벤조푸란-1,4-피페리딘〕류의 제조방법
WO1993001193A1 (fr)	1993-01-21	Composes marins (alcaloides) utiles comme inhibiteurs du vih
AU7595998A (en)	1998-12-30	Sulfate salt of an HIV protease inhibitor having an improved oral absorption and bioavailability
CZ335095A3 (en)	1996-08-14	N-substituted azaheterocyclic carboxylic acids and esters thereof
CZ335595A3 (en)	1996-07-17	N-substituted azaheterocyclic carboxylic acids and their esters, process of their preparation and pharmaceutical compositions containing thereof
CZ12565U1 (cs)	2002-09-02	Dikarboxy-dihydropyridinové deriváty a farmaceutický prostředek